MedPath

Vitamin K1

Generic Name
Vitamin K1
Brand Names
Aquamephyton, Infuvite, Infuvite Pediatric, Mephyton, Mvi Pediatric, Phytonadione
Drug Type
Small Molecule
Chemical Formula
C31H46O2
CAS Number
84-80-0
Unique Ingredient Identifier
S5Z3U87QHF
Background

Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin. Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X. It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity of vitamin K.

Phylloquinone has been synthesized since at least 1939, and was approved by the FDA prior to 1955.

Indication

Oral phylloquinone is indicated to treat prothrombin deficiency caused by coumarin or indanedione derivatives; and hypoprothrombinemia secondary to antibacterial therapy, salicylates, or obstructive jaundice or biliary fistulas with concomitant bile salt administration.

Parenteral (intravenous, intramuscular, and subcutaneous) phylloquinone is indicated to treat coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by vitamin K deficiency or some interference with vitamin K activity. These indications include the above indications as well as hypoprothrombinemia secondary to sprue, ulcerative colitis, celiac disease, intestinal resection, pancreatic cystic fibrosis, or regional enteritis; or hypoprothrombinemia caused by interference with vitamin k metabolism.

Associated Conditions
Coagulation Disorder, Hypoprothrombinemia, Hemorrhagic disease of the newborn
Associated Therapies
Vitamin supplementation

Cadrenal Therapeutics Partners with Abbott to Advance Novel Anticoagulant Trial for LVAD Patients

• Cadrenal Therapeutics and Abbott have formed a strategic collaboration to evaluate tecarfarin, a new oral Vitamin K antagonist, in patients with HeartMate 3 left ventricular assist devices. • Abbott will provide crucial support for the TECH-LVAD trial, including trial design expertise, site identification, and insights from recent HeartMate 3 trials. • The partnership aims to develop the first innovation in vitamin K-targeted anticoagulation in over 70 years, addressing the limitations of warfarin in LVAD patients.
© Copyright 2025. All Rights Reserved by MedPath